Literature DB >> 9814366

Treating phenylketonuria by a phenylalanine-free diet.

K Start.   

Abstract

The phenylalanine-free diet is needed for the treatment of phenylketonuria. Phenylketonuria is an inherited metabolic condition in which there is a deficiency of the enzyme phenylalanine hydroxylase. Lack of this enzyme means the body cannot metabolise the essential amino acid phenylalanine, which then builds up in the blood and causes mental retardation and other abnormalities. Retardation can be prevented if phenylketonuria is diagnosed in the first three weeks of infancy and dietary treatment started straightaway. There is a universal screening test in the UK (the Guthrie test). Heel-prick blood samples are taken from all babies between 6-14 days old and analysed at a regional screening centre. For infants, a phenylalanine-free formula is needed, either as a supplement before breast feeds or following a formula feed. The diet must continue during weaning and childhood, with a low protein diet. Foods such as meat, fish, eggs, milk, cheese, nuts and pulses are excluded as they contain high levels of phenylalanine. Vegetables and fruit are allowed in measured amounts only! Special low protein bread, pasta, biscuits and flour are used to supplement the diet and ensure adequate calorie intake. Whether the diet can be stopped at the end of adolescence is debatable. If stopped, it should be re-started at conception and maintained during pregnancy, as high levels of phenylalanine in the mother can affect the fetus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9814366

Source DB:  PubMed          Journal:  Prof Care Mother Child        ISSN: 0964-4156


  5 in total

Review 1.  Serine and one-carbon metabolism in cancer.

Authors:  Ming Yang; Karen H Vousden
Journal:  Nat Rev Cancer       Date:  2016-09-16       Impact factor: 60.716

2.  Evidence that L-carnitine and selenium supplementation reduces oxidative stress in phenylketonuric patients.

Authors:  A Sitta; C S Vanzin; G B Biancini; V Manfredini; A B de Oliveira; C A Y Wayhs; G O S Ribas; L Giugliani; I V D Schwartz; D Bohrer; S C Garcia; M Wajner; C R Vargas
Journal:  Cell Mol Neurobiol       Date:  2010-12-30       Impact factor: 5.046

3.  L-carnitine blood levels and oxidative stress in treated phenylketonuric patients.

Authors:  Angela Sitta; Alethéa G Barschak; Marion Deon; Jurema F de Mari; Amanda T Barden; Camila S Vanzin; Giovana B Biancini; Ida V D Schwartz; Moacir Wajner; Carmen R Vargas
Journal:  Cell Mol Neurobiol       Date:  2008-09-24       Impact factor: 5.046

4.  Prioritization of Variants for Investigation of Genotype-Directed Nutrition in Human Superpopulations.

Authors:  Pascal D Nilsson; Jacklyn M Newsome; Henry M Santos; Martin R Schiller
Journal:  Int J Mol Sci       Date:  2019-07-18       Impact factor: 5.923

Review 5.  Brain Branched-Chain Amino Acids in Maple Syrup Urine Disease: Implications for Neurological Disorders.

Authors:  Jing Xu; Youseff Jakher; Rebecca C Ahrens-Nicklas
Journal:  Int J Mol Sci       Date:  2020-10-11       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.